Preferred Label : tebentafusp;
UNII : N658GY6L3E;
Origin ID : C000719808;
UMLS CUI : C5139666;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3412130/fr/kimmtrak-tebentafusp-melanome-de-l-uvee
2023
false
false
false
France
uveal neoplasms
uveal melanoma
treatment outcome
insurance, health, reimbursement
tebentafusp
Unresectable Uveal Melanoma
Metastatic Uveal Melanoma
adult
infusions, intravenous
HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive
evaluation of the transparency committee
melanoma
tebentafusp
---
https://ansm.sante.fr/tableau-acces-derogatoire/tebentafusp
2023
false
false
false
France
French
drug information
tebentafusp
uveal melanoma
---
https://www.has-sante.fr/jcms/p_3444067/fr/kimmtrak-tebentafusp-melanome-de-l-uvee
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
Metastatic Uveal Melanoma
adult
uveal melanoma
Unresectable Uveal Melanoma
tebentafusp
HLA-A*02:01 antigen
HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive
evaluation of the transparency committee
melanoma
uveal neoplasms
tebentafusp
---
https://www.ema.europa.eu/en/medicines/human/EPAR/kimmtrak
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tebentafusp
tebentafusp
orphan drug production
adult
uveal melanoma
Metastatic Uveal Melanoma
Unresectable Uveal Melanoma
drug approval
europe
uveal neoplasms
melanoma
infusions, intravenous
Cytokine Release Syndrome
product surveillance, postmarketing
pregnancy
breast feeding
HLA-A*02:01 antigen
tebentafusp
---
https://www.cadth.ca/fr/tebentafusp
2022
false
false
false
false
Canada
French
English
tebentafusp
drug information
tebentafusp
---
https://www.has-sante.fr/jcms/p_3312637/fr/tebentafusp-immunocore
https://www.has-sante.fr/jcms/p_3312644/fr/decision-n-2022-0035/dc/sem-du-27-janvier-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-tebentafusp-immunocore
https://www.has-sante.fr/jcms/p_3318920/fr/decision-n-2022-0063/dc/sem-du-17-fevrier-2022-du-college-de-la-haute-autorite-de-sante-modifiant-la-decision-n-2022-0035/dc/sem-du-27-janvier-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-tebentafusp-immunocore
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
tebentafusp
uveal melanoma
Metastatic Uveal Melanoma
Unresectable Uveal Melanoma
adult
infusions, intravenous
HLA-A*0201 Positive Cells Present
survival analysis
continuity of patient care
tebentafusp
HLA-A*02:01 antigen
summary of product characteristics
tebentafusp
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3359041/fr/kimmtrak-tebentafusp-immunocore-melanome-uveal
https://www.has-sante.fr/jcms/p_3359048/fr/decision-n2022-0247/dc/sem-du-13-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-modification-de-l-autorisation-d-acces-precoce-de-la-specialite-kimmtrak
2022
false
false
false
France
guidelines for drug use
uveal neoplasms
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Metastatic Uveal Melanoma
Unresectable Uveal Melanoma
HLA-A*0201 Positive Cells Present
adult
tebentafusp
evaluation of the transparency committee
tebentafusp
uveal melanoma
melanoma
---
